At GTx, we focus on the development of small molecules that selectively modulate the effects of certain hormones produced by the body. We are developing selective androgen receptor modulators, also referred to as SARMs, to potentially treat a number of serious diseases, including breast cancer, stress urinary incontinence and Duchenne muscular dystrophy. To further explore treatments targeting diseases caused by abnormal androgen receptor signaling, we have a preclinical program to develop selective androgen receptor degraders (SARDs) for prostate cancer patients who no longer respond to androgen deprivation therapy.
Type
Public
HQ
Memphis, US
Founded
1997
Employees
29 (est)
GTx was founded in 1997 and is headquartered in Memphis, US

Key People at GTx

Mitchell S. Steiner

Mitchell S. Steiner

Chief Executive Officer and Vice Chairman of Board of Directors
Marc S. Hanover

Marc S. Hanover

President and Chief Operating Officer

GTx Locations

Memphis, US

GTx Metrics

GTx Summary

Market capitalization

$1.07 B

Closing share price

$0.78
GTx's latest market capitalization is $1.07 B.

GTx Market Value History

GTx News

GTx Company Life

You may also be interested in